Cargando…

VEGF-A modulates expression of inhibitory checkpoints on CD8(+) T cells in tumors

Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Voron, Thibault, Colussi, Orianne, Marcheteau, Elie, Pernot, Simon, Nizard, Mevyn, Pointet, Anne-Laure, Latreche, Sabrina, Bergaya, Sonia, Benhamouda, Nadine, Tanchot, Corinne, Stockmann, Christian, Combe, Pierre, Berger, Anne, Zinzindohoue, Franck, Yagita, Hideo, Tartour, Eric, Taieb, Julien, Terme, Magali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322048/
https://www.ncbi.nlm.nih.gov/pubmed/25601652
http://dx.doi.org/10.1084/jem.20140559
Descripción
Sumario:Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8(+) T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.